MAP PHARMACEUTICALS, INC.

MAP Pharmaceuticals, Inc.
Investor Relations Department
2400 Bayshore Pkwy.
Suite 200
Mountain View, CA 94043
United States

Visit IR website
Sign-up for email alerts

NASDAQ: MAPP [1]	
Last Trade:	24.98
Trade Time:	4:11 PM ET Mar 1, 2013
Change:	-0.02 (0.076%)
Day Range	24.98 - 25.01
52-Week Range	11.11 - 25.03
Volume	1,074,100
Market Cap. ($M)	883.828
Shares Out (M)	35.380

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

MAP Pharmaceuticals is an innovative drug company focused on providing better treatments for patients with neurological diseases. Taking an integrated scientific approach, MAP Pharmaceuticals seeks to place better care into patients' hands by enhancing how proven drugs perform, through targeted dosing regimens and novel delivery systems. MAP Pharmaceuticals' goal is to develop treatments that provide patients with greater control, improved efficacy and fewer side effects.... (more)

Stock Performance

Chart is not available for this symbol

Press Releases [View all]

Feb 7, 2013
Allergan, Inc. and MAP Pharmaceuticals, Inc. Announce the Federal Trade Commission Has Granted Early Termination of Waiting Period Under Hart-Scott-Rodino Act

Jan 22, 2013
Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.

Jan 2, 2013
MAP Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

Nov 21, 2012
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX®

Nov 8, 2012
MAP Pharmaceuticals to Present at Upcoming Investor Conferences

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Mar 30, 2012
Annual Report (10-K)

Apr 16, 2012
Definitive Proxy Statement

Nov 6, 2012
Quarterly Report (10-Q)

Jul 27, 2012
Quarterly Report (10-Q)

May 8, 2012
Quarterly Report (10-Q)